How Endo-205 Targets Beta-Catenin—and Where It May Fall Short — Part 3

Watch the original video on TikTok

Full transcript of the original video, lightly edited for readability.

By binding it, Endo-205 blocks beta catenin's interaction with nuclear import machinery. That means beta catenin cannot flood the nucleus the same way, and if it cannot get into the nucleus effectively, it cannot drive the same pro survival, pro invasive transcriptional program. Endo-205 has been seen to help stabilize beta catenin at the cell membrane. That matters because beta catenin at the membrane interacts with E cadherin. E cadherin is involved in cell to cell adhesion. When cells lose that adhesion, they can move toward a more invasive migratory state.

That process is often discussed through epithelial mesenchymal transition, or EMT. So the idea is not only that Endo-205 blocks beta catenin from acting in the nucleus, it may also push beta catenin toward a more controlled structural role at the membrane, that is, the second selectivity layer. Even if the peptide enters a cell, its major consequence should only matter where beta catenin signaling is abnormally activated. In a healthy cell, beta catenin is already regulated. The destruction complex handles excess beta catenin. The pathway is not jammed on.

So interfering with excess cytoplasmic beta catenin should theoretically have less impact in healthy tissue. But in endometriosis, where beta catenin is accumulating and trying to flood the nucleus, Endo-205 could matter a lot more. So the two layer model looks like this first, the lesions acidic micro environment helps Endo-205 enter Second, the lesions. Abnormal WNT. Beta catenin signaling makes Endo-205's intracellular action meaningful. That is the core argument. And honestly, it is a strong concept because it is not trying to kill everything.

It is trying to identify the disease terrain, enter that terrain, and interrupt a disease relevant signaling pathway. That is why Endo-205 is interesting. But now let's deal with the limitations because if we are going to be scientifically honest, we cannot turn this into hype. First limitation human efficacy is not established yet. That is massive. Endo-205 has entered the clinical pathway, but early clinical trials are mainly about safety and tolerability. That means we do not yet know if this will meaningfully shrink lesions, reduce pain, improve fertility, reduce recurrence, or work across different endometriosis phenotypes in real world patients.

A mechanism can be beautiful on paper, but the body is where theories go to be tested. Second limitation. Delivery details remain proprietary. That means we do not fully know the formulation strategy. How is the peptide delivered? How long does it circulate? How does it avoid degradation? How often is dosing needed? What tissue compartments does it reach? How much reaches pelvic lesions? Does it distribute well into deep disease? What is the clearance pattern? Without those details, we can understand the concept, but we cannot fully evaluate the therapeutic practicality.

Third limitation. Metabolic heterogeneity may limit pH dependent entry. This is the Concern I think deserves more attention. If a lesion is made of both glycolytic and oxphos heavy cells then the lesion will not have one uniform pH. The hypoxic glycolytic regions may create the acidic microenvironment Endo-205 needs, but the oxygenated vascularized ox post reliant regions may remain closer to physiological P H. At that more neutral P H. Endo-205's histidine like ionizable residues may remain unprotonated. That means the peptide may stay in its locked hydrophilic state and if it stays locked it may not efficiently translocate across those cell membranes.

So you could have diseased cells with a broken WNT. Beta catenin pathway that end O2O5 theoretically should affect. But the drug may not enter those cells efficiently because the extracellular pH did not activate the peptide. That is the exact limitation. The target inside the cell may be present, but the entry condition outside the cell may not be. This is where the treatment could theoretically miss survival pockets. And if those Oxford heavy survival pockets remain alive, they may continue feeding disease persistence or recurrence.

This is especially important because the cells at the vascularized edge of a lesion maybe some of the most active cells involved in growth, invasion and remodeling. If those cells are less acidic then pH dependent entry may not fully cover the most biologically aggressive parts of the lesion. That is not a small issue. That is the difference between partial lesion pressure And complete lesion clearance. Fourth limitation deep infiltrating endometriosis may be physically difficult to reach. This is another major concern. If Endo-205 relies on reaching the lesion microenvironment, then access matters.

A superficial peritoneum lesion may be easier to reach than a dense fibrotic deep infiltrating nodule buried in tissue. Fibrosis changes diffusion, scar tissue changes penetration. Dense extracellular matrix can act like a wall. So even if part of the lesion is acidic, the real question is can enough peptide get there? Can it penetrate deeply enough? Can it reach the active cells inside the lesion? Can it diffuse through the fibroid architecture? Can it reach bowel lesions, uterosacral lesions, bladder lesions, ovarian lesions, adhesions and deep nodules equally?